Logo image
Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
Journal article - Review   Open access   Peer reviewed

Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives

DeGaulle Chigbu and Bisant A. Labib
Pharmaceuticals (Basel, Switzerland), v 14(7), 658
09 Jul 2021
PMID: 34358085
url
https://doi.org/10.3390/ph14070658View
Published, Version of Record (VoR) Open CC BY V4.0

Abstract

Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology
Vernal keratoconjunctivitis (VKC) is a complex and chronic, multifactorial Th2 cell-mediated chronic ocular surface inflammatory condition that typically affects predominantly male children in hot or warm climates. The primary symptom is intense ocular pruritus, often significant enough to affect activities of daily living. Clinical features differ from simple forms of allergic conjunctivitis in that they are more-or-less confined to the superior tarsus and limbus. There is also a risk of corneal involvement, which leads to irreversible vision loss in approximately 6% of patients. Right now, there is no standardized treatment protocol, and many of the currently available options are not effective in severe and recurrent cases. As such, it is imperative to understand this complex allergic immune response in order to identify future therapeutic targets. This review will focus on potential drug targets in VKC, with particular emphasis on immunomodulators and immunobiologic agents.

Metrics

11 Record Views
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Chemistry, Medicinal
Pharmacology & Pharmacy
Logo image